New 'rules of engagement' with alcohol lobby
By Guyon Espiner of RNZ
New "rules of engagement" for health officials dealing with the alcohol industry are coming after a senior staffer complained a public health manager had been "way too friendly" with booze lobbyists.
In May it was reported that Ross Bell, a manager with the Ministry of Health's Public Health Agency, had close engagement with alcohol lobbyists, who were granted input into the development of alcohol policies. References to a review of safe drinking guidelines were removed from a Health New Zealand website after an alcohol lobbyist complained to Bell.
On the day the story was published, Deputy Director-General of Health Dr Andrew Old sent an email to staff saying Bell had "acted entirely appropriately" in his engagement with the alcohol industry.
"Engaging with industry can, and has, yielded meaningful health gains for New Zealanders in the past - and will do so again," the email said. "However, we also know that some industry interests lead to public health harm, and so our engagement needs to be careful, mature, and intentional."
Old invited Ministry of Health staff to respond. Dr Clair Mills, who provides advice to the Public Health Advisory committee, took issue with the engagement with the alcohol industry.
"I do think there is a problem - at the very least, in terms of perception," she wrote to Old, in emails released under the Official Information Act.
The alcohol industry's fight against Local Alcohol Policies - where communities set their own conditions for sale - revealed its motivations, Mill said. It contrasted with the "lack of community voice and power".
RNZ's reporting revealed a series of emails between Bell and alcohol lobbyists, which showed close relationships, multiple meetings and exchanges of information.
"I think the tone of the emails was way too friendly," Mills, whose career includes serving as Medical Director for Médecins Sans Frontières' and as Medical Officer of Health in Northland, said in her email to Old.
"In my experience… these alcohol interests have zero interest in reducing harm (or sales of booze) and a huge purse to fund their lawyers." 'Perception becomes reality'
Old responded to Mills saying stronger processes for health officials engaging with the alcohol industry were being prepared.
"All good points - perception becomes reality after all," he told her. "Given we are expected to engage with industry, whether that's alcohol, food or anything else (except tobacco!) it would help to have some clear rules of engagement. I'm picking that up with our central MOH team."
Tobacco lobbyists are shut out of policy making because New Zealand is a signatory to the Framework Convention on Tobacco Control (FCTC).
Under the FCTC countries protect policy development from the "vested interests of the tobacco industry" as there is an "irreconcilable conflict between the tobacco industry's interests and public health policy interests".
In contrast, the alcohol industry has input into policy development in New Zealand, including managing Fetal Alcohol Spectrum Disorder (FASD) and spending the Alcohol Levy, a $16 million fund to reduce alcohol harm, estimated in a 2024 report by NZIER to cost $9.1 billion a year.
RNZ used the OIA to obtain 85 pages of emails detailing engagement between the Ministry of Health (MOH) and alcohol lobbyists, with Ross Bell emerging as the main conduit.
One document describes a 90 minute meeting between lobbyists and MOH staff in February 2025 as "Alcohol industry reps and Ministry of Health regular meeting".
The documents show the plan to manage FASD has been given to the alcohol industry. "Thanks for sharing the draft FASD plan," a wine lobbyist says in an email to public health officials, copying in a lobbyist with the spirits industry.
The documents show alcohol lobbyists made their own submissions to MOH on how they believed FASD should be managed.
The Spirits New Zealand submission runs to four pages but is entirely redacted by MOH under a section of the OIA designed to protect "the confidentiality of advice tendered by Ministers of the Crown and officials".
RNZ has asked the Ombudsman to investigate whether the MOH can legitimately use this section of the OIA to protect correspondence from a spirits industry lobbyist. Alcohol industry's input
The documents obtained by RNZ show Bell was receptive to requests from the alcohol industry.
In November 2024 the Brewer's Association complained to Bell that references to a review of the low risk drinking guidelines were still on the Health New Zealand website, alcohol.org.nz, after it had already complained to him about it.
It also took issue that the site linked to what other countries, including Canada, were doing with their advice on low-risk drinking.
Bell intervened in an email to Health New Zealand in December 2024.
"All work on this project will now pause. You will update relevant Health NZ websites to remove references to the review and also to other jurisdictions' guidelines (including the Canadian one)."
Bell refused to be interviewed by RNZ but in a previous statement he said the material was removed from the website to avoid confusion, as the drinking guidelines were now led by the Ministry of Health not Health New Zealand which runs the alcohol.org.nz website.
He said that was an internal decision by MOH and that a review of the drinking guidelines was now on hold while the ministry considered its priorities.
The documents obtained by RNZ show that Bell also shared the Alcohol Levy investment framework with wine and beer lobbyists in a November 2024 email.
"As discussed and as promised, attached is the draft Alcohol Levy Investment Framework for your consideration and feedback," he wrote.
The alcohol lobbyists then provided at least three pages of feedback on how the money should be spent.
But again MOH is keeping all that information secret under the section of the OIA designed to protect "the confidentiality of advice tendered by Ministers of the Crown and officials".
Minister for Mental Health Matt Doocey turned down RNZ's request for information on the Alcohol Levy but did release correspondence from alcohol lobbyists.
Those documents included a July 2024 email to Doocey and his Cabinet colleague Shane Reti where the wine, beer and spirits industries pushed for greater involvement in setting alcohol policy.
"We still believe industry has a lot to offer as government seeks to reduce harmful drinking," the booze lobbyists wrote.
They pointed out that they funded the main education programme which teaches students about the impacts of alcohol.
"We also fund, through our own social investment charity - The Tomorrow Project, an in-school theatre-based better drinking education programme called Smashed," the lobbyists told the Ministers. "Smashed is independently run and delivered by The Life Education Trust and reaches over 20,000 year 9 students every year."
Filings with the Charities Services show that the beer, wine and spirits industries each paid $105,000 towards The Tomorrow Project, a charity entirely funded by the alcohol industry.
The alcohol lobbyists also make a pitch for the government to "partner with industry" in deciding how to spend the Alcohol Levy and say they should be "working directly with officials" on reducing alcohol harm.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
2 hours ago
- Scoop
Government Moves To Further Weaken Freshwater Protections As New Report Highlights Poor State Of NZ Drinking Water
Greenpeace says it is deeply disturbed by the findings of the latest Taumata Arowai report, which shows that seven registered water supplies exceeded levels of nitrate associated with an increased risk of preterm birth. The organisation says it is also concerning that this news comes while the Government is consulting on proposals that would further weaken freshwater protections in Aotearoa. Greenpeace spokesperson Will Appelbe says, "This Government wants to weaken freshwater protections at the worst time, allowing polluting corporations like Fonterra to profit from the contamination of rural communities' drinking water. This latest data from Taumata Arowai shows that, as we already know, water quality in New Zealand is poor. Now, Luxon's Government wants to make it worse." "Everyone, no matter where they live, deserves to have access to clean, safe drinking water. We should all be able to take a dip in the local lake or river without getting sick. But these basic freedoms that all New Zealanders should be able to enjoy are being taken away for the sake of making a few individuals even more wealthy." During 2024, Taumata Arowai received 4 notifications of samples from registered supplies that exceeded the maximum allowable value of 11.3 mg/L for nitrate. Two were for Waimate District Council's Lower Waihao supply, which supplies Glenavy, and two for Te Kowhai School, a rural school near Hamilton. Seven supplies exceeded 5.56 mg/L - the level of nitrate which international studies have shown is associated with an increased risk of preterm birth. "Rural communities are most at risk of contaminated drinking water because of their proximity to intensive dairying - a major source of freshwater pollution in New Zealand," says Appelbe. "Right now, this Government is consulting on a host of Resource Management Act changes that will, in practice, put corporate interests ahead of the health of people and the environment, especially when it comes to freshwater. "These changes will give more prioritisation to corporate uses of water, like intensive dairy. This would enable dairy expansion, which means more effluent, nitrate and pathogens like E. coli polluting New Zealand's rivers and drinking water. "People across the country want change. They want clean, healthy rivers and water that's safe to drink. In Canterbury, one of the hotspots of Aotearoa's freshwater crisis, water protection is set to be a key issue in the upcoming Environment Canterbury elections. Politicians who aim to pollute freshwater should expect resistance."
1News
4 hours ago
- 1News
Wegovy weight loss costs $500 a month — should we fund it?
Rosie, a 43-year-old mother of five from Nelson, has struggled with her weight since her 20s. "Every time I would go to the doctor, I would say 'Hey, I don't think it is normal. I'm quite overweight. Is there something that can help me? "And the answer is always 'diet and exercise, diet and exercise', but I've always eaten well. I've always exercised, like, I lift weights at the gym." A diagnosis at 29 for Polycystic Ovary Syndrome, which could impact weight due to insulin resistance and hormone imbalances, alluded to a possible cause. Finally, in 2024, Rosie's GP prescribed her two weight loss medications over the last nine months. She lost 15kg but her progress on the current medication Saxenda plateaued and Rosie was still 15kg from her goal. ADVERTISEMENT That's why in July she is planning to transition to Wegovy. It is a weekly injectable weight loss medication with a celebrity aura that is available from July 1 in New Zealand after years of overseas success. It is also known as the diabetes medication Ozempic and reduces appetite while silencing food noise. But Rosie, who works in retail with a side hustle to pay for her current weight loss medication, doesn't know if she can afford the potentially $500 monthly cost for Wegovy. While the medication is approved for use by Medsafe, it is not funded by Pharmac. For those who are already using weight loss medication, Wegovy's availability is highly anticipated to decrease their weight further with fewer side effects. The fervent coverage on social media will no doubt attract more attention — and new converts — to medical weight loss. Yet, Wegovy's high monthly cost and lack of government funding in New Zealand puts it out of reach for most people. The notion of funding weight loss drugs is stuck in a political tug-of-war between those who see obesity as a chronic health condition and those who blame obesity on a lack of personal responsibility. One in three New Zealanders over the age of 15 and one in 10 children are considered obese, the third highest amongst OECD countries. Oprah Winfrey revealed in December 2023 that she had been using weight loss medication. (Source: Associated Press) "...We haven't had really effective weight loss medications [in New Zealand] ever really so this is a real boost and it does change the dynamics a lot of obesity management," says Boyd Swinburn, a professor of population nutrition and global health at the University of Auckland. Initially, the drug won't have a big impact because of its lack of affordability, but as other drug makers rush to make similar drugs, the cost will come down, he says. ADVERTISEMENT The challenge with getting funding for costly weight loss drugs like Wegovy is often shackled by "weight bias, the view that people's excess weight is their own silly fault...," says Swinburn. "That kind of thinking, which really goes against the evidence of what's driving obesity here, that does carry into wider views about the deservedness of people with obesity having taxpayer-funded medications." Swinburn pointed to our general acceptance of funding for other ongoing medications used to reduce blood pressure and high cholesterol as a model for how we should view weight loss medication. The UK government has begun funding for Wegovy and the similar medication Mounjaro for some people and only for a two-year cycle for each patient, according to the BBC. The medication is costing the UK taxpayer close to US$7000 per person annually and there are concerns a fast roll-out could overwhelm the UK's National Health Service due to need. However, rising obesity rates could also "bankrupt" the NHS with the high cost of treating obesity-related diseases such as type 2 diabetes and cancer. Novo Nordisk confirmed Wegovy's entry into the New Zealand market and said in a statement that it is in discussions with the New Zealand government to "explore options for broader, more equitable access for patients". The drug maker declined a request for an interview with one of its representatives. Even without government funding in New Zealand, the cost of weight loss medications is essentially subsidised by the reduced grocery bills for patients, according to Dr Gerard McQuinlan, a Wellington-based GP specialising in weight loss. He is planning to transition most of his medical weight loss patients from Saxenda to Wegovy in the coming weeks. "When they worked out how much they were spending on snacks and the foods they were used to — like high calorie, high carb foods and alcohol — it actually balances out the medication's cost. ADVERTISEMENT "They hardly go to a cafe because they're just not interested." Long-term lifestyle change needed — Dave Letele If Wegovy was quickly funded in New Zealand, former professional boxer and community health advocate Dave Letele would be irritated. He founded From the Couch, a 12-week programme that supports mostly Māori and Pasifika people towards a healthy lifestyle. Massey University's research on the programme showed participants lost on average 7kg during the programme with a significant reduction in signs of severe depression. The research suggested the programme was effective in "the holy grail" of weight loss programmes: long-term lifestyle change. Community leader Dave Letele of BBM. (Source: 1News) "It would be annoying if they funded [Wegovy] and not fund programmes like ours. We have a programme that breaks cycles for generations and we don't get much," says Letele, adding there is a waitlist to enter the From the Couch programme in some areas. A new location kicks off in Northland this week with funding from the Department of Internal Affairs. 'I'm not against the drug, like I'm not against the gastric sleeve [weight loss surgery]. Everything has its place, but there is so much more to it that you need to address.' Letele stressed the need for wrap-around services including help with nutrition and fitness as well as psychological support. ADVERTISEMENT Wegovy might be a forever drug for some patients. Numerous studies show that many who stop taking it or similar medications regain much of their weight. Dr Lara Courtenay, a weight loss physician at the MacMurray Centre in Auckland, has prepared many of her patients to transition from Saxenda to Wegovy throughout July. While Wegovy doesn't work for all patients, the weight loss is typically greater, the side effects are reduced and it requires one weekly injection whereas Saxender is injected daily. Dr Lara Courtenay, a weight loss physician at the MacMurray Centre in Auckland. (Source: Breakfast) Courtenay was a GP for seven years before transitioning to the medical weight loss field, describing it as "a very rewarding job". Along with weight loss medication, MacMurray Centre patients get the support of dieticians and psychologists to promote lifestyle change. This increases the possibility that they one day won't need regular weight loss medication, or require a reduced dose, says Courtenay. However, whatever weight loss medication patients are on, once they stop, they face an uphill battle to prevent their body from returning to their set weight, which is their heaviest weight. "What I say to patients is, 'you're a cave person, your cave person is trying to get you back to your set weight',' says Courtenay, 'and our bodies are really good at doing that.' By Serena Solomon of
Scoop
4 hours ago
- Scoop
Empowering AI Use To Improve Access To Medicines
Associate Minister of Health Associate Health Minister David Seymour has empowered Pharmac and Medsafe to explore the utilisation of artificial intelligence (AI) to speed up their processes. 'Faster access to medicines has always been a priority of mine. For many New Zealanders, pharmaceuticals are life or death, or the difference between a life of pain and suffering or living freely,' Mr Seymour says. 'I believe that technology absorption greatly increases productivity and see Al playing a role in a more efficient Pharmac and Medsafe. 'Finding efficiencies in medicine assessment processes means patients can access the treatments they need faster. 'I wrote to Medsafe about the adoption of AI in their processes to speed up assessments. I wanted to see if the use of AI could mean spending less time on tedious, repetitive tasks that often slow down the assessment process. 'I am very encouraged by Medsafe's response (attached). This is something that they have welcomed and recognise could reduce assessment times. Some of the potential uses of AI in future within medicine regulation include: · streamlining our assessment report generation allowing Medsafe to more quickly provide information in the public domain; · assisting with side effect profiles and trend assessments; · assisting with large information dossier assessments as part of the analysis required for decision making on new medicine applications. 'I have also offered my support to Pharmac in empowering it to use Al in its work. I see this being a matter of priority in Pharmac's new data and digital strategy. I have requested information on where some of the potential future uses of Al in Pharmac,' Mr Seymour says. 'Pharmac have responded and will be exploring opportunities for AI to increase medicines access. I look forward to continuing this discussion with them. 'We're committed to ensuring that the regulatory system for pharmaceuticals is not unreasonably holding back access. It will lead to more Kiwis being able to access the medicines they need to live a fulfilling life.'
